Particle.news
Download on the App Store

Oncomatryx Raises €58 Million With Public Backing to Pursue Gipuzkoa Manufacturing Plant

The financing positions the Derio-based cancer biotech to transition into a fully integrated biopharma capable of advancing therapies from lab to market.

Overview

  • Basque Government, Spain’s central government and Kutxa Fundazioa participated in the capital increase reported at approximately €58 million.
  • Oncomatryx plans to build a manufacturing facility in Gipuzkoa to relocate production currently carried out in Taiwan, with the specific site yet to be determined.
  • The company says the funding will accelerate its shift from an R&D-focused biotech to an operation spanning discovery, clinical development and commercialization.
  • Kutxa Fundazioa confirmed a €15 million commitment, citing the project’s value for the region’s life sciences ecosystem.
  • Founded in 2000 by Dr. Laureano Simón, the Derio-based firm develops next-generation therapies targeting hard-to-treat and metastatic cancers.